Preclinical models of antipsychotic drug action.

نویسندگان

  • José L Moreno
  • Javier González-Maeso
چکیده

One of the main obstacles faced by translational neuroscience is the development of animal models of psychiatric disorders. Behavioural pharmacology studies indicate that psychedelic drugs, such as lysergic acid diethylamide (LSD) and dissociative drugs, such as phencyclidine (PCP), induce in healthy human volunteers psychotic and cognitive symptoms that resemble some of those observed in schizophrenia patients. Serotonin 5-HT2A and metabotropic glutamate 2 receptors have been involved in the mechanism of action of psychedelic and dissociative drugs. Here we review recent advances using LSD-like and PCP-like drugs in rodent models that implicate these receptors in the neurobiology of schizophrenia and its treatment.

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Retigabine: Lesser - Known Effects in Preclinical Studies

Retigabine is a novel anticonvulsant with unique mechanism of action. It induces hyperpolarization of the neuronal membrane by activating a specific type of potassium channels (Kv7, KCNQ). Retigabine is approved by EMA as “adjunctive treatment of partial onset seizures with or without secondary generalisation in adults aged 18 years and above with epilepsy”. The purpose of this review is to res...

متن کامل

Receptor Occupancy Is a Common Mechanism Underlying Animal Models of Antipsychotics and Their Clinical Effects

Conditioned avoidance response (CAR) behavior and catalepsy (CAT) are the standard preclinical tests used to predict antipsychotic activity and motor side-effect liability, respectively. Recent data in patients show that striatal dopamine D 2 occupancy predicts antipsychotic response (at 65% D 2 occupancy) and motor side-effects (at greater than 80%). To relate preclinical and clinical findings...

متن کامل

An update of the preclinical profile of lurasidone

Evidence-based Psychiatric Care 2015;1;67-72 Abstract Lurasidone is a novel antipsychotic drug approved by the US Food and Drug Adminstration (FDA) for the treatment of schizophrenia and bipolar disorder in adults, and by the European Medicines Agency (EMA) for the treatment of schizophrenia. This article reviews published preclinical studies, and analyses the pharmacological, behavioural and m...

متن کامل

Preclinical assessment of CNS drug action using eye movements in mice.

The drug development process for CNS indications is hampered by a paucity of preclinical tests that accurately predict drug efficacy in humans. Here, we show that a wide variety of CNS-active drugs induce characteristic alterations in visual stimulus-induced and/or spontaneous eye movements in mice. Active compounds included sedatives and antipsychotic, antidepressant, and antiseizure drugs as ...

متن کامل

Xanomeline and the antipsychotic potential of muscarinic receptor subtype selective agonists.

Binding studies initially suggested that the muscarinic agonist, xanomeline, was a subtype selective muscarinic M(1) receptor agonist, and a potential new treatment for Alzheimer's disease. However, later in vitro and in vivo functional studies suggest that this compound is probably better described as a subtype selective M(1)/M(4) muscarinic receptor agonist. This subtype selectivity profile h...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:
  • The international journal of neuropsychopharmacology

دوره 16 10  شماره 

صفحات  -

تاریخ انتشار 2013